Join us on the latest episode! Our Guest: Frank Watanabe, President & CEO at Arcutis Biotherapeutics.

What you'll get out of this episode:

• Company Focus: Arcutis Biotherapeutics, under Frank Watanabe, is dedicated to treating inflammatory skin conditions, with three FDA-approved products and a fourth pending.
• Significant Milestones: This year, Arcutis launched two new products and partnered with a primary care company to expand its reach.
• Patient-Centric Approach: Arcutis prioritizes patient needs by involving dermatology practitioners and patient insights directly in decision-making.
• Technological Perspective: While acknowledging AI's potential in drug discovery, Arcutis is focused on tangible, current advancements without prematurely implementing AI.
• Expanding Accessibility: Arcutis is actively working to extend its treatments to Medicare and Medicaid markets to support a broader patient demographic.

To Learn More About Our Guest And Their Company:
LinkedIn https://www.linkedin.com/in/frank-watanabe-419711/
Company LinkedIn https://www.linkedin.com/company/arcutis-inc/
Website https://www.arcutis.com/

Our sponsor for this episode are:
Sage Growth Partners https://sage-growth.com/

BioBreakthroughs is part of the Slice of Healthcare podcast network:
LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/

Join us on the latest episode! Our Guests: Aaron Mackey, SVP of AI/Data Science at Lokavant & Jonathan Crowther, Head of Predictive Analytics at Pfizer.

What you'll get out of this episode:

• Causal AI Explained: Aaron Mackey from Lokavant and Jonathan Crowther from Pfizer discuss the capabilities of causal AI in differentiating cause and effect in clinical trials.
• Comparison to Generative AI: The episode breaks down the distinctions between generative AI and causal AI, highlighting the advantages of causal approaches in clinical operations.
• Impact on Clinical Trial Feasibility: The experts explain how causal AI optimizes trial feasibility assessments, leading to more efficient and effective clinical processes.
• Forecasting Clinical Trials with AI: Insight into how causal AI improves data-driven decision-making and addresses the limitations of traditional trial forecasts.

To learn more about our guests and their companies:
Aaron's LinkedIn https://www.linkedin.com/in/aaronmackey/
Jonathan's LinkedIn https://www.linkedin.com/in/crowtherjonathan/

Lokavant LinkedIn https://www.linkedin.com/company/lokavant/
Pfizer LinkedIn https://www.linkedin.com/company/pfizer/

Lokavant Website https://www.lokavant.com/en-us/
Pfizer Website https://www.pfizer.com/

Our sponsor for this episode is:
Sage Growth Partners https://sage-growth.com/

BioBreakthroughs is part of the Slice of Healthcare podcast network:
LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/

Join us on the latest episode! Our Guest: Joerg Ahlgrimm, CEO at SK Pharmteco.

What you'll get out of this episode:

• Joerg Ahlgrimm discusses his journey in the pharmaceutical industry and his role at SK Pharmteco.
• The strategic integration of companies under SK Pharmteco to enhance global CDMO capabilities.
• The importance of a patient-centric approach in driving company success and innovation.
• Challenges and strategies for ensuring operational efficiency and overcoming funding difficulties in biotech.
• Ahlgrimm’s advice for emerging leaders on career growth and maintaining a patient-first focus.

To Learn More About Our Guest And Their Company:
LinkedIn https://www.linkedin.com/in/joerg-ahlgrimm-315a925/
Company LinkedIn https://www.linkedin.com/company/skpharmteco/
Website https://www.skpharmteco.com/

Our sponsor for this episode are:
Sage Growth Partners https://sage-growth.com/

BioBreakthroughs is part of the Slice of Healthcare podcast network:
LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/

Join us on the latest episode! Our Guest: Elliott Green, Co-Founder & CEO at Dandelion Health.

What you'll get out of this episode:

• Elliot Green's transition from Oscar Health to founding Dandelion Health.
• Dandelion Health's innovative approach to real-world data and clinical AI.
• The importance of longitudinal data in advancing precision medicine.
• The potential of AI to accelerate drug development and improve healthcare outcomes.
• Upcoming events where Dandelion Health will share their advancements.

To Learn More About Our Guest And Their Company:
LinkedIn https://www.linkedin.com/in/elliott-green-98433b2/
Company LinkedIn https://www.linkedin.com/company/dandelion-health-ai/
Website https://dandelionhealth.ai/

Our sponsor for this episode are:
Sage Growth Partners https://sage-growth.com/

BioBreakthroughs is part of the Slice of Healthcare podcast network:
LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/

Join us on the latest episode! Our Guest: Nicole K. Paulk, CEO & Founder at Siren Biotechnology.

What you'll get out of this episode:

• Nicole Paulk's early inspiration in gene therapy during her PhD at OHSU.
• The transition from academia to entrepreneurship amid COVID-19.
• Siren Biotechnology's innovative approach with AAV immunogene therapy.
• The challenges and successes in securing funding and navigating regulatory landscapes.
• The exciting transition of Siren Biotechnology from preclinical to clinical trials.

To Learn More About Our Guest And Their Company:
LinkedIn https://www.linkedin.com/in/nicolepaulk/
Company LinkedIn https://www.linkedin.com/company/siren-biotechnology-inc/
Website https://sirenbiotechnology.com/

Our sponsor for this episode are:
Sage Growth Partners https://sage-growth.com/

BioBreakthroughs is part of the Slice of Healthcare podcast network:
LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/

Join us on the latest episode! Our Guest: Sam Cooper, Co-Founder & CTO at Phenomic.

What you'll get out of this episode:

• Sam Cooper shares his journey from Imperial College London to founding Phenomic.
• Phenomic's innovative approach combines AI with biological research.
• The company focuses on developing drugs targeting the tumor stroma.
• Phenomic's partnership with TileDB and Boehringer Ingelheim.
• Advice for budding biotech entrepreneurs from Sam Cooper.

To Learn More About Our Guests and their Companies:
LinkedIn https://www.linkedin.com/in/sam-cooper-537814134/
Company LinkedIn https://www.linkedin.com/company/phenomic/
Website https://phenomic.ai/

Our sponsor for this episode are:
Sage Growth Partners https://sage-growth.com/

BioBreakthroughs is part of the Slice of Healthcare podcast network:
LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/

Join us on the latest episode! Our Guests: Christine Senn, PhD, the SVP of Site-Sponsor Innovation at Advarra & Rohit Nambisan, Co-Founder and CEO at Lokavant.

What you'll get out of this episode:

• Rohit Nambisan discusses Lokavant's approach to leveraging AI in clinical trial feasibility.
• Christine Senn highlights the importance of thorough feasibility processes in rare disease trials.
• The need for diverse site participation and data inputs to improve trial accuracy and efficiency.
• The role of AI and technology in enhancing clinical trial processes.

To learn more about our guests and their companies:
Christine's LinkedIn https://www.linkedin.com/in/christinesenn/
Rohit's LinkedIn https://www.linkedin.com/in/rohitnambisan/

Advarra LinkedIn https://www.linkedin.com/company/advarra/
Lokavant LinkedIn https://www.linkedin.com/company/lokavant/

Advarra Website https://www.advarra.com/
Lokavant Website https://www.lokavant.com/en-us/

Our sponsor for this episode is:
Sage Growth Partners https://sage-growth.com/

BioBreakthroughs is part of the Slice of Healthcare podcast network:
LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/

Join us on the latest episode! Our Guest: Dr. Sam Clark, Founder and CEO at Terran Biosciences.

What you'll get out of this episode:

• Revolutionizing Treatments: Dr. Sam Clark discusses Terran Biosciences' mission to innovate treatments for neurological and psychiatric conditions.
• Innovative Drug Development: The company focuses on creating new mechanisms for treating depression, bipolar disorder, and schizophrenia.
• Smaller, Agile Teams: Terran Biosciences operates with a flat structure, utilizing highly trained experts to solve complex problems.
• Addressing Patent Monopolies: The company aims to break patent monopolies in pharma through innovative approaches and pro-drug strategies.
• Exciting Developments: Dr. Clark teases upcoming announcements, including long-acting and improved drug forms.

To learn more about our guests and their companies:
LinkedIn https://www.linkedin.com/in/sam-clark-md-phd-133139199/
Company LinkedIn https://www.linkedin.com/company/terran/
Website https://terranbiosciences.com/

Our sponsor for this episode are:
Sage Growth Partners https://sage-growth.com/

BioBreakthroughs is part of the Slice of Healthcare podcast network:
LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/